Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment

American Journal of Hematology

Volumn 89, Issue 12, 2014, Pages 1132-1140

  Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID; BORTEZOMIB; CONGO RED; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; TROPONIN T; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

AMYLOIDOSIS; ARTICLE; AUTONOMIC NEUROPATHY; BIREFRINGENCE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; CREATININE BLOOD LEVEL; HUMAN; LIVER FAILURE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RESTRICTIVE CARDIOMYOPATHY; STEM CELL TRANSPLANTATION; SUBCUTANEOUS FAT; SURVIVAL; AGE; BLOOD; BONE MARROW; DRUG EFFECTS; METABOLISM; PATHOLOGY;

AGE FACTORS; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE MARROW; BORONIC ACIDS; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MELPHALAN; PYRAZINES; STEM CELL TRANSPLANTATION; SUBCUTANEOUS FAT; SURVIVAL ANALYSIS; TROPONIN T;

EID: 84922395266     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23828     Document Type: Article

References (121)

1. Zhou P, Comenzo RL, Olshen AB, et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 2008;111:3403-3406.
2. Bhat A, Selmi C, Naguwa SM, et al. Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol 2010;38:97-106.
3. Weiss BM, Hebreo J, Cordaro DV, et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol 2014.
4. Picken MM. Amyloidosis: Where are we now and where are we heading? Arch Pathol Lab Med 2010;134:545-551.
5. Hemminki K, Li X, Forsti A, et al. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health 2012;12:974.
6. Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: An epidemiological study. Br J Haematol 2013;161:525-532.
7. Tang W, McDonald SP, Hawley CM, et al. End-stage renal failure due to amyloidosis: Outcomes in 490 ANZDATA registry cases. Nephrol Dial Transplant 2013;28:455-461.
8. Chee CE, Lacy MQ, Dogan A, et al. Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk 2010;10:177-180.
9. Chen W, Dilsizian V. Molecular imaging of amyloidosis: Will the heart be the next target after the brain? Curr Cardiol Rep 2012;14:226-233.
10. Mabru M, Dacher JN, Bauer F. Left ventricular hypertrophy: Cardiac magnetic resonance may help differentiate amyloidosis from hypertrophic cardiomyopathy. Arch Cardiovasc Dis 2010;103:55-56.
11. Perfetto F, Moggi-Pignone A, Livi R, et al. Systemic amyloidosis: A challenge for the rheumatologist. Nat Rev Rheumatol 2010;6:417-429.
12. Stratta P, Gravellone L, Cena T, et al. Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: A single center experience. Crit Rev Oncol Hematol 2011;79:31-42.
13. England JD, Gronseth GS, Franklin G, et al. Practice parameter: The evaluation of distal symmetric polyneuropathy: The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PMR 2009;1:14-22.
14. Sedaghat D, Zakir RM, Choe J, et al. Cardiac amyloidosis in a patient with multiple myeloma: A case report and review of literature. J Clin Ultrasound 2009;37:179-184.
15. Tsang W, Lang RM. Echocardiographic evaluation of cardiac amyloid. Curr Cardiol Rep 2010;12:272-276.
16. Cheng AS, Banning AP, Mitchell AR, et al. Cardiac changes in systemic amyloidosis: Visualisation by magnetic resonance imaging. Int J Cardiol 2006;113:E21-E23.
17. Siragusa S, Morice W, Gertz MA, et al. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma: A series of 144 cases and a review of the literature. Ann Hematol 2011;90:101-106.
18. Katzmann JA. Screening panels for monoclonal gammopathies: Time to change. Clin Biochem Rev 2009;30:105-111.
19. Shaheen SP, Levinson SS. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect. Clin Chim Acta 2009;406:162-166.
20. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-224.
21. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-1369.
22. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
23. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: A status report. Leuk Lymphoma 2010;51:2181-2187.
24. Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009;55:499-504.
25. von Hutten H, Mihatsch M, Lobeck H, et al. Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol 2009;33:1198-1205.
26. Kieninger B, Eriksson M, Kandolf R, et al. Amyloid in endomyocardial biopsies. Virchows Arch 2010;456:523-532.
27. Petruzziello F, Zeppa P, Catalano L, et al. Amyloid in bone marrow smears of patients affected by multiple myeloma. Ann Hematol 2010;89:469-474.
28. van Gameren II, Hazenberg BP, Bijzet J, et al. Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. Arthritis Care Res (Hoboken) 2010;62:296-301.
29. Trafton W, Libbey C. Abdominal fat tissue aspirate procedure [Internet]. Boston (MA): Boston University School of Medicine [cited 2014 Aug 5]. Available from: http://www.youtube.com/watch?v?5ctYTmxd9gQ.
30. Dahdah MJ, Kurban M, Kibbi AG, Ghosn S. Primary localized cutaneous amyloidosis: A sign of immune dysregulation? Int J Dermatol 2009;48:419-421.
31. Gallivan GJ, Gallivan HK. Laryngeal amyloidosis causing hoarseness and airway obstruction. J Voice 2010;24:235-239.
32. Javed A, Canales BK, Maclennan GT. Bladder amyloidosis. J Urol 2010;183:2388-2389.
33. Roden AC, Aubry MC, Zhang K, et al. Nodular senile pulmonary amyloidosis: A unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study. Hum Pathol 2010;41:1040-1045.
34. Biewend ML, Menke DM, Calamia KT. The spectrum of localized amyloidosis: A case series of 20 patients and review of the literature. Amyloid 2006;13:135-142.
35. Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: Patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006;107:3489-3491.
36. Linke RP, Oos R, Wiegel NM, Nathrath WB. Classification of amyloidosis: Misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem 2006;108:197-208.
37. Gruys E, Ultee A, Upragarin N. Glycosaminoglycans are part of amyloid fibrils: Ultrastructural evidence in avian AA amyloid stained with cuprolinic blue and labeled with immunogold. Amyloid 2006;13:13-19.
38. Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957-4959.
39. Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011;68:195-199.
40. Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012;119:1844-1847.
41. Sethi S, Theis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010;5:2180-2187.
42. Maleszewski JJ, Murray DL, Dispenzieri A, et al. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol 2013;22:189-194.
43. Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: Origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 2013;8:1515-1523.
44. Desai HV, Aronow WS, Peterson SJ, Frishman WH. Cardiac amyloidosis: Approaches to diagnosis and management. Cardiol Rev 2010;18:1-11.
45. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010;3:333-342.
46. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-995.
47. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881-1887.
48. Kumar S, Dispenzieri A, Gertz MA. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008;358:91.
49. Gertz M, Lacy M, Dispenzieri A, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008;49:36-41.
50. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-470.
51. Palladini G, Merlini G. Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis. Oncology (Williston Park) 2011;25:633, 637-638.
52. Chee CE, Rajkumar SV, Gertz MA, et al. Higher plasma cell burden predicts for early death in patients with AL amyloidosis [abstract 1893]. Blood 2010;116.
53. Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: Prognostic value and correlations with clinical features. Blood 2010;116:5126-5129.
54. Gertz MA, Zeldenrust SR. Treatment of immunoglobulin light chain amyloidosis. Curr Hematol Malig Rep 2009;4:91-98.
55. Kumar S, Dispenzieri A, Lacy MQ, et al. Serum uric acid: Novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc 2008;83:297-303.
56. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011;86:12-18.
57. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol 2012;30:4541-4549.
58. Leung N, Glavey SV, Kumar S, et al. A detailed evaluation of the current renal response criteria in AL amyloidosis: Is it time for a revision? Haematologica 2013;98:988-992.
59. Jones NF, Hilton PJ, Tighe JR, Hobbs JR. Treatment of "primary" renal amyloidosis with melphalan. Lancet 1972;2:616-619.
60. Kyle RA, Bayrd ED. Amyloidosis: Review of 236 cases. Medicine (Baltimore) 1975;54:271-299.
61. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients. Blood 1996;88:2801-2806.
62. Dispenzieri A, Merlini G, Comenzo RL. Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego). Biol Blood Marrow Transplant 2008;14(Suppl 1):6-11.
63. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-1093.
64. Mhaskar R, Kumar A, Behera M, et al. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: A systematic review. Biol Blood Marrow Transplant 2009;15:893-902.
65. Mehta J, Dispenzieri A, Gertz MA. High-dose chemotherapy with autotransplantation in AL amyloidosis: A flawed meta-analysis. Biol Blood Marrow Transplant 2010;16:138-140.
66. Gertz MA, Lacy MQ, Dispenzieri A, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant 2013;48:557-561.
67. Madan S, Kumar SK, Dispenzieri A, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 2012;119:1117-1122.
68. Dunn D, Vikas P, Jagasia M, Savani BN. Plerixafor in AL amyloidosis: Improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease. Bone Marrow Transplant 2012;47:1136-1137.
69. Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007;110:3561-3563.
70. Cordes S, Dispenzieri A, Lacy MQ, et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 2012;118:6105-6109.
71. Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: Outcomes before and after 2006. Bone Marrow Transplant 2011;46:970-975.
72. Tsai SB, Seldin DC, Quillen K, et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: Trends in treatment-related mortality over the past 17 years at a single referral center. Blood 2012;120:4445-4446.
73. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response. Haematologica 2007;92:1415-1418.
74. Gertz MA, Lacy MQ, Dispenzieri A, et al. Transplantation for amyloidosis. Curr Opin Oncol 2007;19:136-141.
75. Okuyama H, Yamaya H, Fukusima T, Yokoyama H. A patient with persistent renal AL amyloid deposition after clinical remission by HDM/SCT therapy. Clin Nephrol 2013;79:233-236.
76. Quillen K, Seldin DC, Finn KT, Sanchorawala V. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Bone Marrow Transplant 2011;46:976-980.
77. Madan S, Kumar S, Lacy M, et al. Pre-stem cell transplant induction therapy does not affect post-transplant survival in light chain (AL) amyloidosis [abstract 370]. Blood 2010;116.
78. Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013;31:4319-4324.
79. Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011;86:251-255.
80. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290-298.
81. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-1207.
82. Sanchorawala V, Wright DG, Seldin DC, et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002;117:886-889.
83. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-2938.
84. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110:787-788.
85. Merlini G, Seldin DC, Gertz MA. Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 2011;29:1924-1933.
86. Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008;143:369-373.
87. Dietrich S, Schonland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010;116:522-528.
88. Lin G, Dispenzieri A, Kyle R, et al. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 2013;24:793-798.
89. Gertz MA. I don't know how to treat amyloidosis. Blood 2010;116:507-508.
90. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391-4394.
91. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119:4387-4390.
92. Blade J, Rosinol L. Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies. Clin Lymphoma 2003;3:247-248.
93. Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003;10:257-261.
94. Palladini G, Russo P, Lavatelli F, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009;88:347-350.
95. Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109:457-464.
96. Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 2006;142:1298-1302.
97. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 2007;109:492-496.
98. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: A multicenter phase 1/2 dose-escalation study. Blood 2010;116:4777-4782.
99. Sanchorawala V, Patel JM, Sloan JM, et al. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: Results of a phase II trial. Haematologica 2013;98:789-792.
100. Dinner S, Witteles W, Afghahi A, et al. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica 2013;98:1593-1599.
101. Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: Long-term results from a phase 2 trial. Blood 2012;119:4860-4867.
102. Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013;98:433-436.
103. Kastritis E, Terpos E, Roussou M, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012;119:5384-5390.
104. Specter R, Sanchorawala V, Seldin DC, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 2011;26:881-886.
105. Dispenzieri A, Dingli D, Kumar SK, et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 2010;85:757-759.
106. Palladini G, Russo P, Foli A, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol 2012;91:89-92.
107. Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012;119:5397-5404.
108. Wechalekar AD, Lachmann HJ, Offer M, et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93:295-298.
109. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: Targeted therapy? Haematologica 2007;92:1302-1307.
110. Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study. Blood 2009;114:1489-1497.
111. Tamaki H, Naito Y, Lee-Kawabata M, et al. Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib. Int J Hematol 2010;92:655-658.
112. Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013;27:823-828.
113. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28:1031-1037.
114. Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2011;90:201-206.
115. Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420-3427.
116. Chari A, Barley K, Jagannath S, Osman K. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis. Clin Lymphoma Myeloma Leuk 2013;13:55-61.
117. Columbia University. Bendamustine and dexamethasone in patients with relapsed AL amyloidosis. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [2014 Aug 5]. Available from: http://clinicaltrials.gov/ct2/show/NCT01222260?term=nct01222260&rank=1NLM Identifier: NCT01222260.
118. Herrmann SM, Gertz MA, Stegall MD, et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant 2011;26:2032-2036.
119. Leung N, Griffin MD, Dispenzieri A, et al. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 2005;5:1660-1670.
120. Pinney JH, Lachmann HJ, Sattianayagam PT, et al. Renal transplantation in systemic amyloidosis: Importance of amyloid fibril type and precursor protein abundance. Am J Transplant 2013;13:433-441.
121. Pinney JH, Lachmann HJ, Bansi L, et al. Outcome in renal AL amyloidosis after chemotherapy. J Clin Oncol 2011;29:674-681.